American Century Companies Inc Macrogenics Inc Transaction History

American Century Companies Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$9.77 - $21.47 $117,845 - $258,971	12,062 Added 23.48%	63,428 $933,000
Q4 2023 Feb 13, 2024	BUY	$4.48 - $10.11 $230,119 - $519,310	51,366 New	51,366 $494,000
Q2 2023 Aug 14, 2023	SELL	$4.62 - $7.54 $33,157 - $54,114	-7,177 Reduced 39.29%	11,088 $59,000
Q1 2023 May 11, 2023	BUY	$4.82 - $7.24 $16,739 - $25,144	3,473 Added 23.48%	18,265 $130,000
Q4 2022 Feb 13, 2023	BUY	$3.34 - $6.98 $49,405 - $103,248	14,792 New	14,792 $99,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

Stay updated on American Century Companies Inc with notifications on news.